All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

oteracil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
uracil type antineoplastics	2002	937-13-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: potassium oxonate oxonic acid potassium salt oteracil 5-Azaorotic acid oxonic acid oteracil potassium	Antagonist of urate oxidase. Molecular weight: 157.09 Formula: C4H3N3O4 CLOGP: -2.13 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 107.86 ALOGS: -1.34 ROTB: 1

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2	63
kinase-selectivity-class	ACVR2A,AXL,BRAF,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,MAP2K3,MAP3K14,MAPK7,PIK3CB,PRKDC,SIK2,STK33,TEK,TTK	18
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
March 14, 2011	EMA	Nordic Group BV
March 1, 1999	PMDA	Taiho Pharmaceutical Co, Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	62.43	48.04	21	172	244013	110345093

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:231911	renoprotective agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant tumor of stomach	indication	363349007	DOID:10534
Hormone receptor pozitive breast cancer	indication	417181009
HER2-negative breast cancer	indication	767444009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.67	acidic
pKa2	10.06	acidic
pKa3	0.5	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Uridine 5'-monophosphate synthase	Enzyme	P11172	UMPS_HUMAN	INHIBITOR				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
C0030032	UMLSCUI
OXC	PDB_CHEM_ID
CHEMBL181932	ChEMBL_ID
DB03209	DRUGBANK_ID
4604	PUBCHEM_CID
7729	INN_ID
C489337	MESH_SUPPLEMENTAL_RECORD_UI
2207-75-2	SECONDARY_CAS_RN
5VT6420TIG	UNII
013265	NDDF
015260	NDDF
1286932002	SNOMEDCT_US
708825002	SNOMEDCT_US
D010094	MESH_DESCRIPTOR_UI
CHEBI:80230	CHEBI

Pharmaceutical products:

None